sanofi-aventis (Thailand) Ltd.

Industry and Activities

Pharmaceutical and Consumer Healthcare

Senior Management

  1. Eric Mansion, GM Pharma South East Asia and India & MCO Lead
  2. Bhawna Gandhi, Head of P7C South East Asia and India MCO
  3. Doreen Tan, Corporate Affairs Head South East Asia and India
  4. Faycal  KARKI, CFO South-East Asia and India MCO & Finance Business Partner Pharma
  5. Shiva Patil, SE Asia & India Medical Head, Pharma & CML

The Leadership In Thailand

  1. Mantana Tanprasert, Head of Vaccines, Thailand and Myanmar ( Vaccines Business)
  2. Charles Trolliet, Head of  Commercial Thailand  ( Pharma Business)

Contact Information
Address:
87/2 CRC Tower, 24th Fl., All Seasons Place, Wireless Rd., Lumpini, Pathumwan, Bangkok 10330 Thailand
Phone Number:
+66 (0) 2 264 9999
Fax Number:
+66 (0) 2 264 9998
Products and Services

Our local presence includes:

Pharmaceutical market: Providing leading therapeutic solutions for cardiovascular, thrombosis, diabetes, oncology, internal medicine, rare diseases, and central nervous system

Growing Consumer Healthcare Business Unit led by the feminine hygiene wash Lactacyd And a footprint in rare diseases such as Genetic Lysosomal Storage Disorders (Gaucher, Pompe, MPS and Fabry)

EABC Representative

Name:
Chamaiporn Noonbhakdi

Position:
Thailand Public Affairs and Market Access Head

Contact information for member only.

Company Profile

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes and cardiovascular, vaccines, rare diseases, consumer healthcare, emerging markets.
Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi has its roots in Thailand since 1965 when Hoechst Pharmaceutical Industries registered, and became sanofi-aventis (Thailand) Ltd in 2006. Sanofi Group is present through 4 entities: Sanofi, Sanofi Pasteur, and the GPOMBP Ltd. (Government Pharmaceutical Organization-Merieux Biological Product), a joint venture between GPO, Sanofi Pasteur and CPB Equity Ltd. dedicated to the downstream production of vaccines for the local public market.